Skip to content
16 November · 06:30 UTCFollow GSK by emailFollow

GSK · Pharma and healthcare · one day

GSK (GSK): news on Sunday 15 November 2026

News from the 24 hours to Sunday morning, 15 November 2026.

Tone of the day

+7.0strongly positive
Relevant headlines6of 12 read
Stories6grouped by event

What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.

Why it scored this way

Coverage leaned positive, led by earnings call commentary pointing to strong growth, a Canadian approval for a hepatitis B therapy and a favourable European regulatory opinion on Bexsero and Talzenna. Other items, such as a former chief executive's new role and a ViiV appointment, were minor.

What drove it

  • earnings call
  • regulatory approvals
  • Bexsero and Talzenna CHMP opinion

Around this day

DayToneHeadlines
Mon 9 Nov−3.33
Tue 10 Nov+6.313
Wed 11 Nov+4.56
Thu 12 Nov+4.512
Fri 13 Nov+4.214
Sat 14 Nov+9.220
Sun 15 Nov+7.06
Mon 16 Nov+2.54

6 stories · 6 headlines · strongest first

Pharma and healthcare on 15 NovemberFTSE 100 that day
ToneWhat the article reported, and why it scored that waySource
GSK earnings call coverage +9.21 headline today · A summary says the earnings call signalled growth despite headwinds.
+9.2Earnings call coverage points to strong growth despite some pressures.</br>TipRanks (opens the article) ↗
EU committee backs GSK's Bexsero meningitis B booster +9.61 headline today · 12 in all, since 14 November · CHMP backed a Bexsero booster dose and a wider Talzenna indication.
+8.3European regulator backs Bexsero booster and wider Talzenna use.TradingView (opens the article) ↗
Canada approves hepatitis B functional-cure therapy +8.31 headline today · Canada has cleared a hepatitis B therapy that is the first to offer a functional cure.
+8.3Canadian approval of first hepatitis B functional-cure treatment, likely GSK's.Streamline Feed (opens the article) ↗
Emma Walmsley named HP CEO-designate +0.81 headline today · Former GSK chief Emma Walmsley was named HP chief executive-designate.
+0.8Former GSK chief takes top job at another firm; minor link.HR Today (opens the article) ↗
ViiV Healthcare appoints HR business leader +0.51 headline today · Shivani Singh was appointed to an HR role at ViiV Healthcare.
+0.5Routine HR appointment at ViiV, a GSK-controlled business.HR Today (opens the article) ↗
GSK share outlook for the week of 16–20 November 0.01 headline today · A preview sets out levels and scenarios for the week.
0.0Share price outlook piece with scenarios, no clear direction.JournalArta (opens the article) ↗

Each article has its own score. The lines are our own summary; follow the source link to read the article itself.

Follow by email

A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.

How it works. Every morning an AI model reads the UK business news about each FTSE 100 company and scores how good or bad it is for the company, from −10 to +10. Pages update by about 07:45 UK time.

Not investment advice. MarketFrame rates the tone of news coverage. It is general information, not a recommendation to buy or sell anything. The scores are not share-price data or forecasts: a good score doesn't mean a share will rise, and a bad one doesn't mean it will fall.

Data to 06:30 UTC, 16 November · 220 headlines · 52 companiesMade by Adapt Progress Evolve Limited, a UK company · Privacy · Terms · Who we are · RSS · API · llms.txt